Market Cap 22.09B
Revenue (ttm) 2.89B
Net Income (ttm) 492.70M
EPS (ttm) N/A
PE Ratio 39.80
Forward PE 41.13
Profit Margin 17.03%
Debt to Equity Ratio 0.07
Volume 819,400
Avg Vol 650,414
Day's Range N/A - N/A
Shares Out 71.91M
Stochastic %K 60%
Beta 1.07
Analysts Strong Sell
Price Target $323.42

Company Profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applicati...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 610 594 2900
Address:
530 Herman O. West Drive, Exton, United States
nikitatrades
nikitatrades Oct. 25 at 6:59 PM
$WST - Beats, Raises, and Reassures The Headline: Strong Q3 beat followed by a guidance raise. The Numbers: EPS: $1.96 (Beat by 16%) Revenue: $804.6M (Beat) Key Takeaway: Raised full-year sales and profit guidance. A confident signal of operational stability and growth.
0 · Reply
IN0V8
IN0V8 Oct. 24 at 7:52 PM
$WST Buy Deutsche Bank raises PT to $345 from $305
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 3:06 PM
UBS has adjusted their stance on West Pharmaceutical Servs ( $WST ), setting the rating to Buy with a target price of 320 → 355.
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 12:34 PM
Keybanc updates rating for West Pharmaceutical Servs ( $WST ) to Overweight, target set at 325 → 350.
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 23 at 9:26 PM
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 23 at 6:48 PM
WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components $WST $AVUS $XRMI https://stocktwits.com/news/equity/markets/wst-stock-soars-after-company-raises-full-year-guidance-on-strong-demand-for-glp-1-drug-components/cLG4YS9R3ro
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 5:54 PM
Evercore ISI Group has updated their rating for West Pharmaceutical Servs ( $WST ) to Outperform with a price target of 390.
0 · Reply
notreload_ai
notreload_ai Oct. 23 at 5:12 PM
$WST raises its 2025 outlook after strong demand for self-injection devices drives revenue and profit above expectations. https://notreload.xyz/west-pharmaceuticals-raises-2025-outlook-as-self-injection-device-sales-surge/
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 4:59 PM
$WST surprise Q3 earnings beat — with a 17.4% EPS estimate beat and revenues up 7.7% year over year, driven by Proprietary Products and Contract-Manufactured Products. 📈 Yet, the stock has lagged the industry and S&P 500's gains this year. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2775686/wst-stock-up-on-q3-earnings-beat-eps-view-raised-on-demand-fx-benefit?cid=sm-stocktwits-2-2775686-body-17343&ADID=SYND_STOCKTWITS_TWEET_2_2775686_BODY_17343
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 3:59 PM
$WST just crushed Q3 — and raised its EPS outlook 🚀 Strong demand, FX tailwinds, and solid growth in Proprietary Products powered the beat, signaling momentum heading into year-end. Full breakdown of the bullish setup here 👉 https://www.zacks.com/stock/news/2775686/wst-stock-up-on-q3-earnings-beat-eps-view-raised-on-demand-fx-benefit?cid=sm-stocktwits-2-2775686-teaser-17341&ADID=SYND_STOCKTWITS_TWEET_2_2775686_TEASER_17341
0 · Reply
Latest News on WST
West to Participate in Upcoming Investor Conferences

Oct 24, 2025, 6:00 AM EDT - 1 day ago

West to Participate in Upcoming Investor Conferences


West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand

Oct 23, 2025, 12:16 PM EDT - 2 days ago

West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand


West Reports Third-Quarter 2025 Results

Oct 23, 2025, 6:00 AM EDT - 2 days ago

West Reports Third-Quarter 2025 Results


West to Host Third-Quarter 2025 Conference Call

Oct 9, 2025, 6:00 AM EDT - 16 days ago

West to Host Third-Quarter 2025 Conference Call


Best Dividend Aristocrats For September 2025

Aug 27, 2025, 2:09 PM EDT - 2 months ago

Best Dividend Aristocrats For September 2025

ABBV ABT ADM ADP AFL ALB AMCR


West Pharmaceutical: Q2 Earnings Suggest Recovery

Jul 30, 2025, 12:20 PM EDT - 3 months ago

West Pharmaceutical: Q2 Earnings Suggest Recovery


West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars

Jul 24, 2025, 10:38 AM EDT - 3 months ago

West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars


West Welcomes Robert McMahon as Incoming Chief Financial Officer

Jul 21, 2025, 6:00 AM EDT - 3 months ago

West Welcomes Robert McMahon as Incoming Chief Financial Officer


West to Host Second-Quarter 2025 Conference Call

Jul 8, 2025, 6:00 AM EDT - 3 months ago

West to Host Second-Quarter 2025 Conference Call


nikitatrades
nikitatrades Oct. 25 at 6:59 PM
$WST - Beats, Raises, and Reassures The Headline: Strong Q3 beat followed by a guidance raise. The Numbers: EPS: $1.96 (Beat by 16%) Revenue: $804.6M (Beat) Key Takeaway: Raised full-year sales and profit guidance. A confident signal of operational stability and growth.
0 · Reply
IN0V8
IN0V8 Oct. 24 at 7:52 PM
$WST Buy Deutsche Bank raises PT to $345 from $305
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 3:06 PM
UBS has adjusted their stance on West Pharmaceutical Servs ( $WST ), setting the rating to Buy with a target price of 320 → 355.
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 12:34 PM
Keybanc updates rating for West Pharmaceutical Servs ( $WST ) to Overweight, target set at 325 → 350.
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 23 at 9:26 PM
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 23 at 6:48 PM
WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components $WST $AVUS $XRMI https://stocktwits.com/news/equity/markets/wst-stock-soars-after-company-raises-full-year-guidance-on-strong-demand-for-glp-1-drug-components/cLG4YS9R3ro
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 5:54 PM
Evercore ISI Group has updated their rating for West Pharmaceutical Servs ( $WST ) to Outperform with a price target of 390.
0 · Reply
notreload_ai
notreload_ai Oct. 23 at 5:12 PM
$WST raises its 2025 outlook after strong demand for self-injection devices drives revenue and profit above expectations. https://notreload.xyz/west-pharmaceuticals-raises-2025-outlook-as-self-injection-device-sales-surge/
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 4:59 PM
$WST surprise Q3 earnings beat — with a 17.4% EPS estimate beat and revenues up 7.7% year over year, driven by Proprietary Products and Contract-Manufactured Products. 📈 Yet, the stock has lagged the industry and S&P 500's gains this year. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2775686/wst-stock-up-on-q3-earnings-beat-eps-view-raised-on-demand-fx-benefit?cid=sm-stocktwits-2-2775686-body-17343&ADID=SYND_STOCKTWITS_TWEET_2_2775686_BODY_17343
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 3:59 PM
$WST just crushed Q3 — and raised its EPS outlook 🚀 Strong demand, FX tailwinds, and solid growth in Proprietary Products powered the beat, signaling momentum heading into year-end. Full breakdown of the bullish setup here 👉 https://www.zacks.com/stock/news/2775686/wst-stock-up-on-q3-earnings-beat-eps-view-raised-on-demand-fx-benefit?cid=sm-stocktwits-2-2775686-teaser-17341&ADID=SYND_STOCKTWITS_TWEET_2_2775686_TEASER_17341
0 · Reply
theoptionsplug
theoptionsplug Oct. 23 at 2:38 PM
Best performers in the S&P so far this morning $LVS $WST $DOW $MPWR
0 · Reply
DonCorleone77
DonCorleone77 Oct. 23 at 12:20 PM
$WST West Pharmaceutical reports Q3 adjusted EPS $1.96, consensus $1.69 -- Q3 revenue $804.6M, consensus $787.7M. -- Ups FY25 adjusted EPS view to $7.06-$7.11 from $6.65-$6.85, consensus $6.78. -- Raises FY25 revenue view to $3.06B-$3.07B from $3.04B-$3.06B, consensus $3.05B. -- Backs FY25 capital spending view $275M.
0 · Reply
Estimize
Estimize Oct. 23 at 10:03 AM
$WST reported - EPS and - revenue for Q3. http://www.estimize.com/intro/wst?chart=historical&metric_name=eps&utm_content=WST&utm_medium=act
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 11:51 AM
Enter: $WST NOV 21 2025 $280 CALLS Buy in Price: $14.80 - $15.54 Take Profit: $34.34 Stop Bleeding: $13.02 ROI Potential: 132% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 20 at 9:18 PM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 1:51 PM
Enter: $WST NOV 21 2025 $280 CALLS Buy in Price: $12.80 - $14.60 Take Profit: $24.06 Stop Bleeding: $11.26 ROI Potential: 88% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Oct. 17 at 2:29 PM
Can $WST maintain its earnings surprise streak? 🔍 WST has beaten earnings estimates in the last four quarters, with an average surprise of 16.81%. For Q3, organic revenue is expected to grow 2.5% to 3.5%, but EPS is projected to decline 9.7% YoY. Full Q3 preview here 👉 https://www.zacks.com/stock/news/2770951/wst-q3-earnings-preview-can-glp-1-momentum-outweigh-margin-pressure?cid=sm-stocktwits-2-2770951-body-16565&ADID=SYND_STOCKTWITS_TWEET_2_2770951_BODY_16565
0 · Reply
ZacksResearch
ZacksResearch Oct. 17 at 1:29 PM
$WST Q3 preview — bullish demand, bearish margins? Strong GLP-1 and biologics demand could lift revenue, but labor issues, tariffs, and plant shutdowns are pressing on margins. The big question: can growth outmuscle the cost squeeze? Full earnings setup here 👉 https://www.zacks.com/stock/news/2770951/wst-q3-earnings-preview-can-glp-1-momentum-outweigh-margin-pressure?cid=sm-stocktwits-2-2770951-teaser-16564&ADID=SYND_STOCKTWITS_TWEET_2_2770951_TEASER_16564
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 1:41 AM
Enter: $WST NOV 21 2025 $270 CALLS Buy in Price: $15.64 - $16.50 Take Profit: $36.28 Stop Bleeding: $13.76 ROI Potential: 132% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 12:28 PM
Is $WST a buy amid GLP-1 boom? 🤔 Despite a 20.3% drop so far this year, West Pharmaceutical is riding high on GLP-1 demand and high-value product momentum, with earnings expected to grow 8.4% over the next five years 📈. However, tariff risks and operational challenges could temper growth. Dive into the details here 👉 https://www.zacks.com/stock/news/2768974/reasons-to-retain-west-pharmaceutical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2768974-body-16096&ADID=SYND_STOCKTWITS_TWEET_2_2768974_BODY_16096
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 11:28 AM
$WST — Still worth holding? Here’s why the story’s not over yet. GLP-1 demand and high-value products are driving solid growth potential for West Pharmaceutical, even as tariffs and execution risks pressure margins. See why the long-term case still holds 👉 https://www.zacks.com/stock/news/2768974/reasons-to-retain-west-pharmaceutical-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2768974-teaser-16095&ADID=SYND_STOCKTWITS_TWEET_2_2768974_TEASER_16095
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 12 at 5:56 PM
Enter: $WST NOV 21 2025 $270 CALLS Buy in Price: $11.60 - $16.50 Take Profit: $23.90 Stop Bleeding: $10.21 ROI Potential: 106% Exit Within: 199 Minutes https://moneygroup.us/alerts
0 · Reply